Clinical Trial Update: QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating QR-Bromocriptine as an adjunct to insulin and metformin in type 2 diabetes has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• QR-Bromocriptine (bromocriptine)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED | Results posted: 2019-09-16